Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-6624 dose-ranging trial in primary sclerosing cholangitis
2012-002473-61Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing GS-6624 arm with Placebo arm (2 arms). Started Mar 2013; status: completed.
02
Drugs
simtuzumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2012-002473-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002473-61.